|
Luye Pharma Group Ltd
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Luye Pharma Group Ltd Headquarters 137 Telok Ayer Street, #05-05, ; Singapore; 068602 Legal Address Clarendon House, 2 Church Street; Hamilton; HM11 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational ISIN CODE : BMG062191025 Financial Auditors: Ernst & Young Certified Public Accountants (2005) Incorporation Date: July 2, 2003 Tel: (65) 62200119 |
|
Company Description |
| The Group specialises in the research, development, production and sale of pharmaceutial drugs and new formulations for chemical drugs, the sale of R&D results and patents for new drugs, and the provision of research services on a contract basis. The Group is in the business of: (1) research, development, production and sale of pharmaceutical drugs for the fields of orthopaedics, neurology, gastroenterology and hepatology, focusing on natural drugs and chemical drugs with new formulations; (2) | ||
|
||
Company Analysis |
| According to the Consolidated - Non-Audited financial statement for the first quarter of 2011, total net operating revenues increased with 20.38%, from CNY 307,512 thousands to CNY 370,179 thousands. Operating result decreased from CNY 62,332 thousands to CNY 49,912 thousands which means -19.93% change. The results of the period decreased -26.79% reaching CNY 32,686 thousands at the end of the period against CNY 44,647 thousands last year. Return on equity (Net income/Total equity) went from 4.34% to 2.84%, the Return On Asset (Net income / Total Asset) went from 2.74% to 1.73% and the Net Profit Margin (Net Income/Net Sales) went from 14.52% to 8.83% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 53.00% compared to 47.56% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 2.02 to 1.84 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2011 Q1 (cons) |
2010 Y (cons) |
|
 | ||
| Non-Audited | Audited | |
| ||
| CEIC Company Financials (New) | CEIC Company Financials (New) | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
1,887,537 |
1,822,167 |
| ||
Current Assets |
952,901 |
895,360 |
| ||
Total Liabilities |
609,860 |
573,984 |
| ||
Shareholders Equity |
1,150,656 |
1,126,445 |
| ||
Current Liabilities |
517,343 |
458,999 |
| ||
| * All the accounts are in CNY. | ||
Income Statement
| ||
Total Revenues |
370,179 |
1,340,895 |
| ||
Operational Profit (Loss) |
49,912 |
201,892 |
| ||
Net Profit (Loss) |
32,686 |
150,404 |
| ||
| * All the accounts are in CNY. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
1.73% |
8.25% |
| ||
Annualised Return on Assets (ROA) |
6.92% |
8.25% |
| ||
Return on Equity (ROE) |
2.84% |
13.35% |
| ||
Annualised Return on Equity (ROE) |
11.36% |
13.35% |
| ||
Return on Sales (ROS) |
13.48% |
15.06% |
| ||
Return on Capital |
2% |
9.98% |
| ||
Gross Profit Margin |
84.26% |
84.77% |
| ||
Operating Profit Margin |
7.4% |
10.15% |
| Efficiency Ratios | ||
| ||
Inventory Turnover |
0.01x |
0.03x |
| ||
Current asset turnover |
0.00x |
0.01x |
| ||
Fixed-asset turnover |
0.01x |
0.04x |
| ||
Asset Turnover |
0.00x |
0.01x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
49,912 |
201,892 |
| ||
EBITDA |
73,335 |
272,101 |
| ||
Enterprise value |
509,572 |
504,125 |
| ||
Enterprise Value / EBITDA |
6.95 |
1.85 |
| ||
Bookvalue (BV) |
1,150,656 |
1,126,445 |
| ||
Net Cash |
422,287 |
400,135 |
| Liquidity Ratios | ||
| ||
Current Ratio |
1.84% |
1.95% |
| ||
Quick ratio |
1.7% |
1.79% |
| ||
Doom's day ratio |
0.92% |
0.99% |
| ||
Cash Flow to Debt |
0.02% |
0.01% |
| Leverage Ratios | ||
| ||
Leverage ratio |
1.64% |
1.62% |
| ||
Interest Coverage Ratio |
11.66% |
17.83% |
| ||
Debt to equity |
53% |
50.96% |
| ||
Debt to total assets |
0.17% |
0.15% |
| ||
Debt / Enterprise Value |
0.61% |
0.53% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
44.19 |
11.98 |
| ||
Price/Book Ratio |
2.44 |
2.45 |
| ||
Market Cap / Net cash |
7.67 |
8.15 |
| ||
Market cap/Shareholder equity |
2.82 |
2.89 |
| Trend Ratios | ||
| ||
Revenue Trend |
0% |
1.4% |
| ||
Net Income Trend |
0.67% |
1.1% |
| ||
Operating Income Trend |
0.8% |
1.25% |
| ||
 |